Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07965081981 Ext: 4 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
EBITDA stood at Rs 517.4 crore in Q4 FY26, up 32.2% YoY. EBITDA margin improved to 14.4% in Q4 FY26 as against 12.4% in Q4 FY25.
During the quarter, R&D expenses stood at Rs 229.3 crore, up 44.67% compared with Rs 158.5 crore in Q4 FY25 and accounted for 6.4% of total revenue. India sales were Rs 2,324.5 crore in Q4 FY26, YoY growth of 8.8%. International sales stood at Rs 1,222.3 crore, up 25.4% YoY.
On an annual basis, the company's consolidated net profit rose 6.3% to Rs 2,301.80 crore in FY26 compared with Rs 2,165.48 crore in FY25. Revenue from operations jumped 13.48% to Rs 14,712.27 crore in FY26 compared with Rs 12,964.52 crore in FY25.
Vikas Gupta, CEO of Alkem, said, 'We are pleased to report that Alkem has recorded its highest ever EBIDTA in FY26, reaffirming the strength of our growth strategy, execution and operational rigour. Our top-line growth was broad-based with both domestic branded generics and international business delivering strong growth. An improving business mix, operating leverage and continued cost discipline drove meaningful margin expansion in FY26.
Our financial performance in Q4 was also marked by strong revenue and EBITDA growth as well as a significant increase of 40.7% in our profit before tax and exceptional item. We enter FY27 on a firm foundation and expect healthy growth across businesses supported by increasing contribution from chronic therapies and a differentiated launch pipeline for international markets.'
Meanwhile, the company's board recommended a final dividend of Rs 10 per equity share of Rs 2 each for financial year ended 31 st March, 2026. The company fixed record date as 7th August, 2026 for final dividend. It will be paid on and from 1st September 2026.
Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products.
Th counter advanced 1.36% to end at Rs 5,452.25 on the BSE. The stock market remained closed today on account of Bakri Id.
Powered by Capital Market - Live News